Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands
Stephané Roze,1 Jayne Smith-Palmer,2 Simona de Portu,3 Alexis Delbaere,3 Bonnie de Brouwer,4 Harold W de Valk5 1HEVA HEOR, Lyon, France; 2Ossian Health Economics and Communications, Basel, Switzerland; 3Medtronic International Trading Sàrl, Tolochenaz, Switzerland; 4Medtronic Trading NL, Heerlen, the Netherlands; 5Leiden University Medical Center, Leiden, the Netherlands Aim: The aim of this study was to perform a cost-effectiveness analysis to establish the cost-effectiveness of sensor-augmented pump therapy (SAP) with automated insulin suspension vs continuous subcutaneous insulin infusion (... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2019 |
Reihe/Periodikum: | ClinicoEconomics and Outcomes Research, Vol Volume 11, Pp 73-82 (2019) |
Verlag/Hrsg.: |
Dove Medical Press
|
Schlagwörter: | Cost / cost-effectiveness / type 1 diabetes / the Netherlands / sensor-augmented insulin pump therapy / Medicine (General) / R5-920 / Therapeutics. Pharmacology / RM1-950 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26800562 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doaj.org/article/324f35e4bfc845288b9717b7d6bf9e74 |